课题基金 / 基金详情

Understanding the Microbiome-gut-brain axisn Alzheimer disease and its Role in Cognitive Decline

Understanding the Microbiome-gut-brain axisn Alzheimer disease and its Role in Cognitive Decline
了解微生物组-肠-脑轴阿尔茨海默病及其在认知能力下降中的作用
批准号:
9974848
负责人:
John Patrick Haran
金额:
$328.14万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-15 至 2024-08-31

项目摘要

项目成果

John Patrick Haran的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 “微生物区系-肠道-脑轴”的概念起源于微生物群的行为研究-- 重组的小鼠,目前的研究表明,支持微生物组可能对一些 最具破坏性的神经退行性疾病,包括阿尔茨海默病(AD)。最近的研究表明 询问了肠道微生物组之间的这种联系,并确定了丰度的显著变化 阿尔茨海默病患者的某些分类群。因此,目前的一种理论认为,AD的发病机制与失衡密切相关 肠道微生物群中的细菌,可能起源于肠道。我们的研究小组最近在一群人中发表了研究结果 养老院老人在AD老人中表现出一种反常的模式,其特点是 具有抗炎特性的细菌的流行,以及已知会导致 支持炎症的状态。在这项建议中,我们将:1)利用我们目前的养老院经验来招收老年人 评估认知衰退;2)推动我们在当地老年中心老年群体内的工作,以登记 3)确定其中的微生物区系分类和基因功能 老年人;4)利用粪便样本来确定微生物群如何引起肠道炎症以及如何 这与观察到的全身炎症有关;5)研究微生物组代谢产物 并解释这些产品如何影响小胶质细胞的功能。我们假设有一个 无论生活环境如何,阿尔茨海默病老年人的非生物特征微生物群水平 炎症性生态失调与局部和全身炎症呈正相关,最终 认知能力下降。我们进一步假设AD微生物组代谢产物对小胶质细胞有负面影响 功能正常。具体地说,在目标1中,我们将从不同的角度评估AD老年人的微生物群特征 与非痴呆症老年人相比的环境和纵向评估微生物组组成 并将其与认知的变化联系起来。在目标2中,我们将确定微生物群失调的程度 AD老年人,这与诱导(体内/体外)上皮功能障碍的水平相关,然后回到老年人身上 炎症细胞因子标记物和免疫衰老T细胞群标记物。最后,在目标3中,我们将 进行代谢组学研究以确定AD老年人和非痴呆者之间的代谢物谱差异 并在我们的体内/体外试验中使用已确定的代谢物来描述其对小胶质细胞功能的影响。这 这项工作向前迈出了关键的一步,通过展示AD如何在微生物群与AD之间的因果关系之间架起桥梁 观察到的老年人微生物群失调会对肠上皮细胞动态平衡造成不利影响,导致全身性 炎症,炎症引起的免疫衰老,最终导致认知功能障碍。它还将 描述微生物代谢产物的差异以及这些代谢产物如何影响小胶质细胞的功能。 了解这一至关重要的“微生物-肠道-脑轴”如何影响AD的发展和进展将提供 新的治疗靶点,并使旨在干预这些途径的未来试验成为可能。
英文摘要
ABSTRACT The concept of the “microbiota-gut-brain axis”, which originated from behavioral studies in microbiome- reconstituted mice, has advanced to current research that supports the microbiome may be responsible for some of the most devastating neurodegenerative disorders, including Alzheimer's Disease (AD). Recent studies have interrogated this connection among the intestinal microbiome and identified significant changes in the abundance of certain taxa in AD patients. Thus, one current theory is that AD pathogenesis is closely related to the imbalance of the gut microbiome and may originate in the gut. Our group has recently published findings among a cohort of nursing home elders demonstrating a dysbiotic pattern in AD elders that is hallmarked by a reduction in the prevalence of bacteria with anti-inflammatory properties, as well as an acquisition of taxa that are known to cause pro-inflammatory states. In this proposal we will: 1) leverage our current nursing home experience to enroll elders assessing cognitive decline; 2) advance our work within the local Senior Centers' elder groups to enroll a comparative community-dwelling cohort; 3) determine both microbiota taxonomy and gene function among these elders; 4) utilize stool samples to determine how the microbiome can induced intestinal inflammation and how this correlates back to observed systemic inflammation; and 5) study the microbiome metabolic product differences and explain how these products can influence microglia functioning. We hypothesize that there is a characteristic dysbiotic microbiome among AD elders, regardless of living environment, and that the level of inflammation-type dysbiosis positively correlates with both local and systemic inflammation and eventually cognitive decline. We further hypothesize that the AD microbiome metabolites negatively impact microglial functioning. Specifically, in Aim 1 we will assess characteristics of the AD elder's microbiome from different environments in comparison to elders without dementia and longitudinally assess the microbiome composition and correlate it to changes in cognition. In Aim 2 we will determine the extent of microbiome dysbiosis among AD elders, correlate this with the level of induce (in vivo/vitro) epithelial dysfunction, and then back to elder cytokine markers of inflammation and T cell population markers of immunosenescence. Finally, in Aim 3 we will perform metabolomics to identify metabolite profile differences between AD elders and those without dementia and use the identified metabolites in our in vivo/vitro assays to describe its effects on microglial functioning. This work takes a critical step forward to bridge microbiome associations with AD to causality by showing how the AD elder's microbiome dysbiosis observed can adversely affect intestinal epithelial homeostasis leading to systemic inflammation, inflammation-causing immunosenescence, and ultimately cognitive dysfunction. It will also describe the microbial metabolic product differences and how these metabolites influence microglial functioning. Understanding how this crucial “microbiota-gut-brain axis” impacts AD development and progression will provide novel therapeutic targets and enable future trials aimed at intervening upon these pathways.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
The elderly gut microbiome during transition to long-term care and the risk of Clostridium difficile carriage
The elderly gut microbiome during transition to long-term care and the risk of Clostridium difficile carriage
The elderly gut microbiome during transition to long-term care and the risk of Clostridium difficile carriage
海外基金